Business / Finance

RSS

Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances.

From Quest Diagnostics 25 Feb 2013

Novel anti-cancer drug conjugates to be evaluated by Ablynx and Spirogen

Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary technology platform.

25 Feb 2013

Blaze Bioscience completes $8.5 million Series A financing

Blaze Bioscience, Inc., a biotechnology company dedicated to developing innovative products to improve the lives of cancer patients, today announced the completion of a Series A financing totaling $8.5 million and bringing the total funds raised since inception to $9.8 million.

22 Feb 2013

Majority of businesses are not adequately prepared for many types of disasters

A recent study by Saint Louis University researchers found that majority of businesses are not adequately prepared for many types of disasters, especially biological events such as a pandemic.

22 Feb 2013

Medidata Solutions fourth quarter net revenues increase 24% to $58.6 million

Medidata Solutions, a leading global provider of cloud-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the fourth quarter and full year 2012, and provided detailed financial guidance for the first quarter and full year 2013.

21 Feb 2013

Push for electronic medical records leads to profits for some companies

The approach came in 2009, in a presentation to doctors by Allscripts Healthcare Solutions of Chicago, a well-connected player in the lucrative business of digital medical records.

21 Feb 2013

Medisafe 1 Technologies intends to issue one-time special dividend to all shareholders

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company intends to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to SAFECODE DRUG TECHNOLOGIES CORP.

20 Feb 2013

Healthcare Realty revenues increase to $81.3M for three months ended December 31, 2012

Healthcare Realty Trust Incorporated today announced results for the fourth quarter ended December 31, 2012.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

ICICI Lombard General Insurance Company launches new ad campaign

Insurance is all about a 'Promise'. A promise that needs to be fulfilled during the hour of need. This is a unique category where the value of the product is realised not at the time of purchase but sometime in future when an unfortunate event/accident occurs for which the insurance cover was purchased. It is this 'moment of truth' that separates one insurance company from the other in terms of whether or not a claim is settled and the speed of settlement thus adequately compensating the insured for the loss.

20 Feb 2013

iCAD fourth quarter total revenue increases 18% to $7.8 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2012.

19 Feb 2013

Solta Medical fourth quarter revenue increases 20% to $39.8 million

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.

19 Feb 2013

Oncolytics Biotech to commence underwritten public offering of common shares

Oncolytics Biotech Inc. announced today its intention, subject to market and other conditions, to commence an underwritten public offering of common shares. The number of common shares to be distributed and the price of each common share will be determined in the context of the market with final terms to be determined at the time of pricing.

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

NeuroMetrix fourth quarter total revenues decrease to $1.5 million

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today reported business and financial highlights for the quarter and twelve months ended December 31, 2012.

19 Feb 2013

Government of Québec announces $10M investment in Personalized Medicine Partnership for Cancer

The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC).

16 Feb 2013

LifePoint Hospitals fourth quarter revenues increase 14.3% to $893.3 million

LifePoint Hospitals, Inc. today announced results for the fourth quarter and year ended December 31, 2012.

15 Feb 2013

Shengtai second quarter net sales increase 49.31% to $64,103,621

Shengtai Pharmaceutical, Inc., a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended December 31, 2012.

15 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Cardinal Health announces plans to acquire AssuraMed

Cardinal Health today announced plans to acquire privately held AssuraMed, a leading provider of medical supplies to patients in the home, for $2.07 billion, or $1.94 billion, net of the present value of tax benefits.

15 Feb 2013